Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital of Xi'an Jiaotong UniversityActive in the last 2 years

Yanmin Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7307-9408; OpenAlex author ID A5066930734. Sources: OpenAlex.

Their work

Papers
4 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
3
Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 4

  1. Homoharringtonine Impedes Migration and Invasion by Inhibiting EphB4/SRI/EMT Signaling and Enhances the Antimetastatic Abilities of Erlotinib in Pancreatic Can… Co-author DOI 10.2174/0115680096423484251129063926↗
  2. Homoharringtonine sensitizes pancreatic cancer to erlotinib by direct targeting and miRNA-130b-3p-mediated EphB4-JAK2-STAT3 axis. Last author DOI 10.1093/jpp/rgad055↗
  3. Targeting mitochondrial dysfunctions in pancreatic cancer evokes new therapeutic opportunities. Last author DOI 10.1016/j.critrevonc.2022.103858↗
  4. MiRNAs directly targeting the key intermediates of biological pathways in pancreatic cancer. Last author DOI 10.1016/j.bcp.2020.114357↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ammar Sarwar · 3 shared papers, 2021–2023 · strength 0.55
  2. Sarwar Ammar · 1 shared paper, 2026 · strength 0.27
  3. Zixi Zhang · 1 shared paper, 2026 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.